Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Morgan Stanley Maintains Equal-Weight on PPL, Raises Price Target to $32
Morgan Stanley analyst Stephen Byrd maintains PPL (NYSE:PPL) with a Equal-Weight and raises the price target from $31 to $32.
What 7 Analyst Ratings Have To Say About PPL
PPL (NYSE:PPL) has observed the following analyst ratings within the last quarter:
Argus Research Downgrades PPL to Hold
Argus Research analyst Jacob Kilstein downgrades PPL (NYSE:PPL) from Buy to Hold.
Morgan Stanley Maintains Equal-Weight on PPL, Raises Price Target to $31
Morgan Stanley maintains PPL (NYSE:PPL) with a Equal-Weight and raises the price target from $30 to $31.
Members Of Congress Buy Energy, Defense Stocks Prior To Russian Invasion Of Ukraine: Who They Are, What They Bought
Prior to the invasion of Ukraine by Russia and the levying of numerous sanctions on Russia by the U.S., members of Congress purchased defense and energy stocks. Here’s a look at the trades.
Wolfe Research Upgrades PPL to Outperform, Raises Price Target to $30
Wolfe Research analyst Steve Fleishman upgrades PPL (NYSE:PPL) from Peer Perform to Outperform and raises the price target from $28 to $30.